Prelude Capital Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Prelude Capital Management’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-14,800	Closed	-$100K	–	2196
2022 Q1	$100K	Buy	14,800 +2,000	+16%	+$14.3K	﹤0.01%	1412
2021 Q4	$107K	Buy	+12,800	New	+$105K	﹤0.01%	1709
2021 Q3	–	Sell	-11,400	Closed	-$78K	–	2130
2021 Q2	$78K	Buy	+11,400	New	+$94.7K	﹤0.01%	1498
2020 Q4	–	Sell	-200	Closed	-$2K	–	2171
2020 Q3	$2K	Buy	+200	New	+$1.24K	﹤0.01%	1696
2020 Q1	–	Sell	-4,300	Closed	-$38K	–	2185
2019 Q4	$38K	Buy	+4,300	New	+$23.2K	﹤0.01%	1441
2018 Q4	–	Sell	-3,293	Closed	-$21K	–	2267
2018 Q3	$21K	Buy	3,293 +993	+43%	+$7.38K	﹤0.01%	1309
2018 Q2	$18K	Buy	+2,300	New	+$33.2K	﹤0.01%	1376

Other funds holding JNCE

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

Prelude Capital Management's JNCE Position: Q2 2022 in Review

Prelude Capital Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2022, closing a stake of 14,800 shares — an estimated $100K sold.

Prelude Capital Management first reported a position in JNCE in Q2 2018 and held it in 7 quarters. The position peaked at $107K in Q4 2021. 102 funds tracked by Wall St. Rank hold JNCE as of Q2 2022.

Prelude Capital Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Prelude Capital Management sold 14,800 Jounce Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $100K.
Prelude Capital Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2018 and held it in 7 quarters.
Prelude Capital Management's Jounce Therapeutics, Inc. Common Stock position peaked at $107K in Q4 2021.
102 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Prelude Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.